Evelo Biosciences

Cambridge, United States Founded: 2015 • Age: 11 yrs
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.

About Evelo Biosciences

Evelo Biosciences is a company based in Cambridge (United States) founded in 2015.. Evelo Biosciences has raised $166.5 million across 4 funding rounds from investors including Flagship Pioneering, Celgene and Google Ventures. Evelo Biosciences has completed 1 acquisition, including Epiva Therapeutics. Evelo Biosciences operates in a competitive market with competitors including Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx, among others.

  • Headquarter Cambridge, United States
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Evelo Biosciences, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $0
    0
    as on Dec 31, 2022
  • Net Profit
    $-114.53 M
    6.26
    as on Dec 31, 2022
  • EBITDA
    $-103.51 M
    7.03
    as on Dec 31, 2022
  • Total Equity Funding
    $166.5 M (USD)

    in 4 rounds

  • Latest Funding Round
    $25.5 M (USD), Post-IPO

    Jul 10, 2023

  • Investors
  • Employee Count
    Employee Count
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Evelo Biosciences

Evelo Biosciences is a publicly listed company on the OTC with ticker symbol EVLO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: OTC · Ticker: EVLO . Sector: Health technology · USA
People of Evelo Biosciences
Headcount 50-200
Employee Profiles 13
Board Members and Advisors 7
Employee Profiles
People
Laura Jackson
Scientist
People
Aylwin Ng
Head of Systems Immunology
People
Amrita Bhattacharjee
Senior Scientist
People
Janae Peel
Data Entry Clerk

Unlock access to complete

Funding Insights of Evelo Biosciences

Evelo Biosciences has successfully raised a total of $166.5M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25.5 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round Post-IPO — $25.5M
  • First Round

    (04 Nov 2015)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2023 Amount Post-IPO - Evelo Biosciences Valuation

investors

Mar, 2018 Amount Series C - Evelo Biosciences Valuation

investors

Jul, 2017 Amount Series B - Evelo Biosciences Valuation Flagship Pioneering , Google Ventures
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Evelo Biosciences

Evelo Biosciences has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Flagship Pioneering, Celgene and Google Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Life sciences-focused venture capital firm
Founded Year Domain Location
Corporate backed venture capital fund investing in multiple sectors
Founded Year Domain Location
Early stage investments focused VC firm
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Evelo Biosciences

Evelo Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Epiva Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Microbiome-based therapeutics are developed for autoimmune diseases.
2015
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Evelo Biosciences

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Evelo Biosciences Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Evelo Biosciences

Evelo Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ironwood Pharma, RedHill Biopharma, Alcresta, Seed and Ardelyx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for gastrointestinal disorders, including linaclotide, are developed.
domain founded_year HQ Location
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases
domain founded_year HQ Location
Enzyme-based products for gastrointestinal disorders are developed using immobilization technology.
domain founded_year HQ Location
Synbiotics are developed for simulating the gut microbiome.
domain founded_year HQ Location
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Evelo Biosciences

Frequently Asked Questions about Evelo Biosciences

When was Evelo Biosciences founded?

Evelo Biosciences was founded in 2015.

Where is Evelo Biosciences located?

Evelo Biosciences is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.

Who is the current CEO of Evelo Biosciences?

Simba Gill is the current CEO of Evelo Biosciences.

Is Evelo Biosciences a funded company?

Evelo Biosciences is a funded company, having raised a total of $166.5M across 4 funding rounds to date. The company's 1st funding round was a Series B of $50M, raised on Nov 04, 2015.

What does Evelo Biosciences do?

Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer. The company focuses on discovering and developing a new class of orally delivered medicines to modulate the immune system through SINTAX, the small intestinal axis. The product pipeline inlcudes EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer.

Who are the top competitors of Evelo Biosciences?

Evelo Biosciences's top competitors include Ironwood Pharma, Ardelyx and RedHill Biopharma.

Is Evelo Biosciences publicly traded?

Yes, Evelo Biosciences is publicly traded on OTC under the ticker symbol EVLO.

How many acquisitions has Evelo Biosciences made?

Evelo Biosciences has made 1 acquisition, including Epiva Therapeutics.

Who are Evelo Biosciences's investors?

Evelo Biosciences has 5 investors. Key investors include Flagship Pioneering, Celgene, Google Ventures, Acks, and Mayo Clinic Ventures.

What is Evelo Biosciences's ticker symbol?

The ticker symbol of Evelo Biosciences is EVLO on OTC.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available